Bottom line
Is JFNCX a good fund? The bottom line
JFNCX is the Class C share class of Janus Henderson Global Life Sciences Fund, a managed global stock mutual fund from Janus Henderson.
Annual fees run 1.79% — about $179 a year on every $10,000 invested, more expensive than 90% of global stock funds we track.
With $5.8 billion in net assets and 108 holdings, its largest position is Eli Lilly & Co. (9.4%) and the top 10 make up 42.4% of the portfolio.
What stands out
- No front-end sales load
What to watch
- Expensive for its category (1.79%)
- 12b-1 marketing fee of 1% a year
Updated Nov 19, 2026
What JFNCX invests in
Janus Henderson Global Life Sciences Fund seeks long-term growth of capital.
The Fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that portfolio management believes have a life science orientation. In the Funds pursuit of companies with a life science orientation, the Fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the life sciences sector, which may include companies in the following industry groups: pharmaceuticals; biotechnology; health care services; agriculture; cosmetics/personal care; and medical devices. Generally speaking, the life sciences relate to maintaining or improving quality of life. So, for example, companies with a life science orientation include companies engaged in research, development, production, or distribution of…
From the fund's prospectus (filed Jan 28, 2026).
What JFNCX costs
On a $10,000 investment, JFNCX's 1.79% expense ratio costs about $179 a year. The prospectus estimates $1,897 in total costs over 10 years (assuming 5% annual returns). The median global stock fund charges 0.95%.
JFNCX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Eli Lilly & Co. | 9.41% |
| 2 | Johnson & Johnson | 7.09% |
| 3 | AbbVie, Inc. | 4.67% |
| 4 | UnitedHealth Group, Inc. | 4.54% |
| 5 | AstraZeneca plc | 3.93% |
| 6 | Revolution Medicines, Inc. | 3.02% |
| 7 | Argenx SE | 2.63% |
| 8 | Novartis AG | 2.56% |
| 9 | Thermo Fisher Scientific, Inc. | 2.33% |
| 10 | Praxis Precision Medicines, Inc. | 2.19% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 42.4% of the fund. See all top 25 holdings and asset mix →